TY - JOUR
T1 - Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
AU - on behalf of the Groupe Francophone des Myélodysplasies (GFM)
AU - Tarfi, Sihem
AU - Harrivel, Véronique
AU - Dumezy, Florent
AU - Guy, Julien
AU - Roussel, Mikael
AU - Mimoun, Aguirre
AU - Fenaux, Pierre
AU - Chapuis, Nicolas
AU - Solary, Eric
AU - Selimoglu-Buet, Dorothée
AU - Wagner-Ballon, Orianne
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14 ++ CD16 − classical monocyte fraction ≥ 94% of the total monocytes was proposed to rapidly and efficiently distinguish chronic myelomonocytic leukemia from reactive monocytosis. The robustness of this assay required a multicenter validation. The flow cytometry assay designed to quantify peripheral blood monocyte subsets was implemented by multiple diagnosis laboratories in France. A nationwide survey was performed to evaluate its performance. All the 48 French laboratories answered the questionnaire, revealing that 63% use this assay routinely. Central blind reanalysis of 329 cytometry files collected from five laboratories demonstrated an excellent correlation in classical monocyte fraction measurement (r = 0.93; p < 0.0001). The cutoff value of 94% classical monocytes being the critical readout for diagnosis, we then compared 115 patients with classical monocytes ≥ 94% and 214 patients with a fraction < 94% between initial analysis and reanalysis. An agreement was obtained in 311 files. Finally, an overt diagnosis, available for 86 files, confirmed a good sensitivity (93.6%) and specificity (89.7%). This survey demonstrates the robustness of the flow assay with limited variability of classical monocyte percentage between centers, validates the 94% cutoff value, and confirms its sensitivity and specificity.
AB - Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14 ++ CD16 − classical monocyte fraction ≥ 94% of the total monocytes was proposed to rapidly and efficiently distinguish chronic myelomonocytic leukemia from reactive monocytosis. The robustness of this assay required a multicenter validation. The flow cytometry assay designed to quantify peripheral blood monocyte subsets was implemented by multiple diagnosis laboratories in France. A nationwide survey was performed to evaluate its performance. All the 48 French laboratories answered the questionnaire, revealing that 63% use this assay routinely. Central blind reanalysis of 329 cytometry files collected from five laboratories demonstrated an excellent correlation in classical monocyte fraction measurement (r = 0.93; p < 0.0001). The cutoff value of 94% classical monocytes being the critical readout for diagnosis, we then compared 115 patients with classical monocytes ≥ 94% and 214 patients with a fraction < 94% between initial analysis and reanalysis. An agreement was obtained in 311 files. Finally, an overt diagnosis, available for 86 files, confirmed a good sensitivity (93.6%) and specificity (89.7%). This survey demonstrates the robustness of the flow assay with limited variability of classical monocyte percentage between centers, validates the 94% cutoff value, and confirms its sensitivity and specificity.
UR - http://www.scopus.com/inward/record.url?scp=85056579894&partnerID=8YFLogxK
U2 - 10.1038/s41408-018-0146-8
DO - 10.1038/s41408-018-0146-8
M3 - Article
C2 - 30429467
AN - SCOPUS:85056579894
SN - 2044-5385
VL - 8
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 11
M1 - 114
ER -